Thymosin beta-4 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-01-14. Numbers and descriptions here follow the published literature rather than marketing material.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
| Property | Value | Notes |
|---|---|---|
| Reported sequence | Ac-LKKTETQ | Described in most listings as the actin-binding region of thymosin beta-4 |
| Reported molecular weight | Approximately 889 Da | Value shifts with the stated sequence; compare against the certificate of analysis |
| Parent protein length | 43 amino acids | Thymosin beta-4; the fragment covers only a small part of it |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Trade-style names rather than formal nomenclature |
| Formal monographs | Not established | Labeling conventions differ by supplier and region |
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
Kaplan (1922), acting chancellor of University of Maryland, Baltimore County and president of Baltimore Hebrew University Frederick Burkhardt (1933), president emeritus of the American Council of Learned Societies and third president of Bennington College James S. Coles (1936), ninth president of Bowdoin College William C. Fels (1937), fourth president of Bennington College George James (1937), commissioner of Health of the City of New York, dean of the Mount Sinai School of Medicine, president of Mount Sinai Health System James C. Fletcher (1940), president of the University of Utah and administrator of the National Aeronautics and Space Administration Herbert A. Deane (1942), political scientist, vice provost of Columbia University Martin Meyerson (1942), president of the University of Pennsylvania Henry S. Coleman (1946), acting dean of Columbia College, Columbia University during the Columbia University protests of 1968 Steven Marcus (1948), George Delacorte Professor in the Humanities and dean of Columbia College Carl Hovde (1950), professor of English and dean of Columbia College following the Columbia University protests of 1968 Rudolph H. Weingartner (1950), former provost of the University of Pittsburgh, former dean of the College of Arts and Sciences at Northwestern University Ralph Lowenstein (1951), dean of the University of Florida College of Journalism and Communications Michael I. Sovern (1951), president of Columbia University Richard N.
== Definition, regulatory aspects == The International Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, a 2015 Swiss NGO of pharmaceutical companies and others, defined a contract research organization (CRO), specifically pertaining to clinical trials services as: "A person or an organization (commercial, academic, or other) contracted by the sponsor to perform one or more of a sponsor's trial-related duties and functions." It further details the sponsor's responsibilities in its good clinical practice guidelines:
== Overdose == CPA is relatively safe in acute overdose. It is used at very high doses of up to 300 mg/day by mouth and 700 mg per week by intramuscular injection. For comparison, the dose of CPA used in birth control pills is 2 mg/day. There have been no deaths associated with CPA overdose. There are no specific antidotes for CPA overdose, and treatment should be symptom-based. Gastric lavage can be used in the event of oral overdose within the last 2 to 3 hours.
== Pharmacology == Taxifolin is not mutagenic and less toxic than the related compound quercetin. It acts as a potential chemopreventive agent by regulating genes via an ARE-dependent mechanism. Taxifolin has shown to inhibit the ovarian cancer cell growth in a dose-dependent manner. However, in this same study, taxifolin was the least effective flavonoid in the inhibition of VEGF expression. There is also a strong correlation (with a correlation coefficient of 0.93) between the antiproliferative effects of taxifolin derivatives on murine skin fibroblasts and human breast cancer cells. Taxifolin has shown to have anti-proliferative effects on many types of cancer cells by inhibiting cancer cell lipogenesis. By inhibiting the fatty acid synthase in cancer cells, taxifolin is able to prevent the growth and spread of cancer cells. Taxifolin also stops the effects of overexpression of P-glycoprotein, which prevents the development of chemoresistance. Taxifolin does this via inhibition of rhodamine 123 and doxorubicin. The capacity of taxifolin to stimulate fibril formation and promote stabilization of fibrillar forms of collagen can be used in medicine. Also taxifolin inhibited the cellular melanogenesis as effectively as arbutin, one of the most widely used hypopigmenting agents in cosmetics. Taxifolin also enhances the efficacy of conventional antibiotics such as levofloxacin and ceftazidime in vitro, which have potential for combinatory therapy of patients infected with methicillin-resistant Staphylococcus aureus (MRSA).
Sources: en.wikipedia.org
=== Hearing loss === Hearing loss in Treacher Collins syndrome is caused by deformed structures in the outer and middle ear. The hearing loss is generally bilateral with a conductive loss of about 50–70 dB. Even in cases with normal auricles and open external auditory canals, the ossicular chain is often malformed. Attempts to surgically reconstruct the external auditory canal and improve hearing in children with TCS have not yielded positive results. Auditory rehabilitation with bone-anchored hearing aids (BAHAs) or a conventional bone conduction aid has proven preferable to surgical reconstruction.
The Chinese cobra (Naja atra) is a highly venomous member of the true cobras (genus Naja). Its venom consists mainly of postsynaptic neurotoxins and cardiotoxins. Four cardiotoxin-analogues I, II, III, and IV, account for about 54% of the dry weight of the crude venom and have cytotoxic properties. The LD50 values of its venom in mice are 0.29 mg/kg IV, and 0.29 – 0.53 mg/kg SC. The average venom yield from a snake of this species kept at a snake farm was about 250.8 mg (80 mg dry weight). According to Minton (1974), this cobra has a venom yield range of 150 to 200 mg (dry weight). Brown listed a venom yield of 184 mg (dry weight). It is one of the most prevalent venomous snakes in mainland China and Taiwan, which has caused many snakebite incidents to humans.
== Capture of Constantinople == When the Nicaean force reached the village of Selymbria, some 30 miles (48 km) west of Constantinople, they learned from some independent local farmers (thelematarioi) that the entire Latin garrison, as well as the Latin-allied Venetian fleet, was absent conducting a raid against the Nicaean island of Daphnousia in the Black Sea. Strategopoulos initially hesitated to take advantage of the situation, fearing that his small force might be destroyed if the Latin army returned too soon, and because he would exceed the provisions of the emperor's orders, but eventually decided he could not squander such a remarkable opportunity to seize the city without a prolonged siege.
Sources: en.wikipedia.org
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.
No. Thymosin beta-4 is a protein of 43 amino acids, while TB-500 is described as a short fragment of it. The two differ in size, structure, and the range of interactions each can support.
Naming for research peptides is not centrally coordinated, so vendors set their own labels and specifications. Differences in stated sequence, molecular weight, or purity documentation usually trace back to those independent labeling choices.
Sealed, desiccated and protected from light, at -20 °C or lower for long-term storage. Short-term storage at refrigerator temperature is common in working laboratories.